Evidence map›Paper›PMID 25896244›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2015

Experimental Curative Fluorescence-guided Surgery of Highly Invasive Glioblastoma Multiforme Selectively Labeled With a Killer-reporter Adenovirus.

Shuya Yano, Shinji Miwa, Hiroyuki Kishimoto, Makoto Toneri, Yukihiko Hiroshima, Mako Yamamoto, Michael Bouvet, Yasuo Urata, Hiroshi Tazawa, Shunsuke Kagawa and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Shuya YanoAntiCancer, Inc., San Diego, California, USA; Department of Surgery, University of California San Diego, San Diego, California, USA; Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Shinji MiwaAntiCancer, Inc., San Diego, California, USA; Department of Surgery, University of California San Diego, San Diego, California, USA.
Hiroyuki KishimotoDepartment of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Makoto ToneriAntiCancer, Inc., San Diego, California, USA; Department of Surgery, University of California San Diego, San Diego, California, USA.
Yukihiko HiroshimaAntiCancer, Inc., San Diego, California, USA; Department of Surgery, University of California San Diego, San Diego, California, USA.
Mako YamamotoAntiCancer, Inc., San Diego, California, USA; Department of Surgery, University of California San Diego, San Diego, California, USA.
Michael BouvetDepartment of Surgery, University of California San Diego, San Diego, California, USA.
Yasuo UrataOncolys BioPharm Inc., Tokyo, Japan.
Hiroshi TazawaCenter for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
Shunsuke KagawaDepartment of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Toshiyoshi FujiwaraDepartment of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Robert M HoffmanAntiCancer, Inc., San Diego, California, USA; Department of Surgery, University of California San Diego, San Diego, California, USA. Electronic address: all@anticancer.com.
University of California, San Diego · USOkayama University · JPAntiCancer (United States) · USOkayama University Hospital · JPOncolys BioPharma (Japan) · JP

Funding

Fluorophore-Conjugated Antibodies for Imaging and Resection of GI TumorsR01CA142669 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOUVET, MICHAEL, YANG, MENG · 2010 to 2015
$1.7M
Color-Coded Imaging of Pancreatic Cancer Microenvironment for Drug DiscoveryR01CA132971 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOUVET, MICHAEL, YANG, MENG · 2009 to 2013
$1.7M
NCI NIH HHS CA132971NCI NIH HHS CA142669NCI NIH HHS R01 CA132971NCI NIH HHS R01 CA142669
6 · The paper itself

Abstract

Fluorescence-guided surgery (FGS) of cancer is an area of intense current interest. However, although benefits have been demonstrated with FGS, curative strategies need to be developed. Glioblastoma multiforme (GBM) is one of the most invasive of cancers and is not totally resectable using standard bright-light surgery (BLS) or current FGS strategies. We report here a curative strategy for FGS of GBM. In this study, telomerase-dependent adenovirus OBP-401 infection brightly and selectively labeled GBM with green fluorescent protein (GFP) for FGS in orthotopic nude mouse models. OBP-401-based FGS enabled curative resection of GBM without recurrence for at least 150 days, compared to less than 30 days with BLS.

Indexed as

FluorescenceAdenoviridaeAnimalsCell Line, TumorDisease-Free SurvivalDisease Models, AnimalGlioblastomaGreen Fluorescent ProteinsHumansMiceMice, NudeNeoplasm Recurrence, LocalOptical ImagingGreen Fluorescent Proteins

Identifiers

PMID25896244
PMCPMC4817790
OpenAlexW1973709689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.